Tag: Ryanodex

Cardiovascular collapse with marked hyperkalemia has been reported in patients who received dantrolene alongside calcium channel blockers. This highlights a crucial warning regarding what should not be given with RYANODEX, a medication used for malignant hyperthermia. Ensuring patient safety depends on adhering to prescribing guidelines.

First introduced in 1967, dantrolene sodium, originally marketed under the brand name Dantrium, is a postsynaptic muscle relaxant used primarily to treat muscle spasticity. When asking, "What is another name for Dantrium?" the answer refers to its generic name, dantrolene, and other brands such as Revonto and Ryanodex.

The mortality rate for malignant hyperthermia plummeted from 70-80% to under 10% after the introduction of dantrolene sodium. In a medical emergency, knowing **what is the difference between Dantrium and RYANODEX**, two intravenous formulations of this critical drug, can be life-saving for patients susceptible to this rare and dangerous condition.

Malignant hyperthermia (MH) is a life-threatening, inherited pharmacogenetic disorder with a mortality rate that has drastically decreased due to effective treatment. A key part of this treatment involves Ryanodex (dantrolene sodium), and understanding **how does Ryanodex work** is crucial for its rapid deployment in a crisis situation.

First synthesized in 1967, Dantrolene sodium was eventually commercialized under the brand name Dantrium. The question of who makes Dantrium has a complex answer involving several companies, as both branded and generic versions have come to market over the decades.